MDxHealth Stock

MDxHealth FCF Conversion

Delisted·Dec 15, 2023

The FCF Conversion Rate (FCF/EBITDA) of MDxHealth (MDXH.BR) as of Aug 13, 2026 is 34.53 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 54.35 % — a change of -36.46% (lower).

FCF Conversion

34.53 %

YoY

-36.46%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of MDxHealth is 2026 34.53 % . FCF Conversion Rate (FCF/EBITDA) of MDxHealth was 2025 54.35 % . It decreases by -36.46% lower compared to the previous year.
Access this data via the Eulerpool API

MDxHealth Stock analysis

What does MDxHealth do? MDxHealth SA was founded in 2003 and is a publicly traded company based in Belgium, specializing in the development and marketing of molecular diagnostic tests for cancer diagnosis. The company focuses on developing tests for the diagnosis of prostate, bladder, and kidney cancer, as well as tests for monitoring the progression of these cancer types. The business model of MDxHealth is to develop state-of-the-art molecular diagnostics for cancer medicine and make them accessible to medical professionals and pathologists. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth also provides support to its customers in interpreting test results and choosing the best treatment options for patients. The company has different divisions tailored to the specific needs of patients, doctors, and pathologists. The main divisions are the oncology division and the urology division. In the oncology division, MDxHealth offers various tests for prostate cancer, including the Prognostic Oncotype DX Test used for predicting the progression of prostate cancer. The urology division of MDxHealth focuses on developing tests for bladder cancer and kidney cancer. The key tests in this division include the ConfirmMDx Test used for diagnosing bladder cancer, and the SelectMDx Test used for diagnosing aggressive prostate cancer. MDxHealth also has a significant presence in genomics and personalized medicine. The company partners with the University of Miami Miller School of Medicine to research and improve the application of genetic tests in cancer diagnosis and treatment. MDxHealth also collaborates closely with other leading research institutions and cancer centers to drive innovation in molecular diagnostics. Overall, MDxHealth offers a wide range of molecular diagnostic tests for cancer diagnosis and monitoring. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth is a key player in the field of molecular diagnostics and has the potential to improve the lives of cancer patients worldwide. MDxHealth is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MDxHealth stock

FCF Conversion Rate (FCF/EBITDA) of MDxHealth is 34.53 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of MDxHealth changed from 54.35 % to 34.53 %, representing a -36.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) MDxHealth since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s MDxHealth with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — MDxHealth

All Key Metrics — MDxHealth